7 December 2015 - Kite Pharma, Inc. today announced that the U.S. FDA has granted Breakthrough Therapy Designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma, primary mediastinal B cell lymphoma  and transformed follicular lymphoma. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

For more details, go to: http://amda-2v2xoy.client.shareholder.com/releasedetail.cfm?ReleaseID=945790